More than 205 000 new breast cancers are expected to be diagnosed in the United States each year, with an estimated 40 230 annual deaths from the disease (1, 2) . At least half of newly diagnosed patients present with early-stage breast cancer (ESBC), in which the cancer may have spread to nearby lymph nodes but has not metastasized to other parts of the body (1) . As many as 20% of women with ESBC will experience recurrence at a distant site within 10 years after diagnosis (3) . Numerous randomized controlled trials have demonstrated reductions in the rate of distant recurrence in women with ESBC treated with adjuvant chemotherapy (3) . An active area of research has been the development of algorithms that use clinical characteristics and biomarkers to assess the risk of recurrence and likelihood of response to adjuvant chemotherapy, thereby improving our ability to identify women who are most likely to benefit from adjuvant chemotherapy (4).
ESBC; some assays also predict response to adjuvant chemotherapy. A 2009 review identified 14 prognostic and/or predictive assays developed or under development for breast cancer (Table 1 ) (9) . Currently, five of these assays are commercially available in the United States (Table 2) .
Methods have been proposed to grade the evidence used in stratifying cancer risk to accommodate newer study designs that are emerging as a consequence of biomarker development. Simon et al. (10) suggest that an appropriately controlled and well-analyzed prospective study using archived tissues provides a level of validation that lies within the quality spectrum between prospective clinical trials and prospective, observational studies. Application of new principles for grading studies in a systematic review of cancer risk stratifiers has yet to be rigorously applied. The primary aim of our study was to systematically grade the Level-of-Evidence (LOE) in studies that assessed the clinical validity/utility of risk stratifiers for ESBC. A secondary aim was to document studies that provided evidence on changes in practice patterns and health economic implications of the stratifiers.
Methods

Assays Included in the Review
We included studies only if the assay(s) addressed have achieved regulatory approval or are performed in a laboratory that is Clinical Laboratory Improvement Amendment certified.
The 21-gene recurrence score (Oncotype DX; Genomic Health, Inc., Redwood City, CA) uses reverse transcription polymerase chain reaction technology on paraffin-embedded tumor tissue, reporting a continuous risk score between 1 and 100 (11, 12) . It also stratifies recurrence risk into three categories: low, intermediate, and high. The 70-gene signature (MammaPrint; Agendia BV, Irvine, CA) uses microarray technology applied to fresh-frozen tissues to stratify patients into good and poor prognosis categories (13) . The 5-gene expression index (Molecular Grade Index; BioTheranostics, San Diego, CA) uses reverse transcription polymerase chain reaction technology to generate a continuous-scale index of the gene ratio (14) . The 5-antibody immunohistochemistry (IHC) panel (Mammostrat; Clarient, Inc., Aliso Viejo, CA) uses an algorithm combining the results of five commercially available IHCs to stratify patients into low, moderate, and high risk categories. The 14-gene signature (BreastOncPx; US LABS, Irvine, CA) uses reverse transcription polymerase chain reaction technology to stratify patients into high or low recurrence risk groups.
Search Strategy
A systematic search of the scientific literature written in English and published from 2000 to 2011 was performed using PubMed (US National Library of Medicine, Bethesda, MD), Cumulative Index to Nursing and Allied Health Literature (EBSCO Publishing, Ipswich, MA), and Cochrane Database of Systematic Reviews (Cochrane Collection; John Wiley & Sons, Ltd., Hoboken, NJ). We supplemented the initial electronic scan by using the Institute of Scientific Information Web of Science (Thomson Reuters, New York, NY) to search for additional citations of key clinical validation studies. Keywords for these database searches included: <breast cancer>, <gene expression or gene expression profiling>, <predict* OR prognos*>, <biomarker>, <21 gene>, <Recurrence Score>, <Oncotype DX>, <70 gene>, <MammaPrint>, <5 monoclonal antibody>, <immunohistochemistry panel>, and <Mammostrat>. We also searched publications from international congresses, such as the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium, and the European Society of Medical Oncology. Ongoing clinical trials were identified through http:// www.clinicaltrials.gov.
Data Extraction
Articles identified by the literature search were independently screened on the basis of their abstracts by two investigators and were excluded if the abstract indicated that no original data was presented (eg, reviews and editorials). We also excluded articles that did not contain an abstract. After the initial screening, the full text of each article was reviewed. Studies were included if they collected and analyzed original data on an assay's independent and statistically significant ability to predict risk of progression or response to chemotherapy in women with ESBC. Studies also were included if they assessed the impact of the stratifier on clinical decisions, practice patterns, or economics. Analyses that combined data from different sources using decision-analytical techniques to assess long-term outcomes and economics were also included. Articles were excluded if they: 1) assessed individual elements of the stratifier but not the entire stratifier; 2) pertained to unrelated topics (eg, pathophysiological studies, in vitro studies); 3) contained no original data; 4) concerned the use of the stratifier in diseases other than ESBC; 5) were not published in English; or 6) did not pertain to the clinical validation, decision impact, or health economic analysis of the risk stratifiers.
Outcome Measures
We examined clinical validity and utility on the basis of the criteria developed by Simon et al. (10) and adapted from Hayes et al. (15) . These authors were concerned that many retrospective studies of prognostic and predictive markers might establish an association with a clinical outcome, but the patients in these studies may not have been "selected for addressing a defined medical indication for the use of the marker" (15) . In their framework, clinical validity is the ability of the assay to predict the clinical endpoint(s) of interest, whereas clinical utility is the balance of associated benefits and risks if the assay is introduced into clinical practice. Three required aspects of utility are described: "…that the test is 'actionable,' that the clinical context and medical indication for use of the test is clear, and that the magnitude of outcomes or treatment effects associated with different results of the test are sufficiently great as to influence treatment" (10) .
The elements of tumor marker studies that are used to generate a LOE determination included characteristics of clinical trial design: 1) patients and patient data; 2) specimen collection, processing, and archival; 3) statistical design and analysis; and 4) consistency in validation results. The elements used to constitute a LOE determination are described in Supplementary Table 1 . In summary, studies assigned to Category A typically represent prospective, randomized clinical trial designs. Category B represents prospective studies using archived tissue samples. Category C represents prospective, observational registry studies in which treatment and follow-up are not dictated. Category D represents retrospective/observational studies. Category B was included in this framework because a positive result from this type of study is less likely to be a "play of chance" than a similar result from a Category C, prospective, observational registry.
Our LOE determination also follows Simon et al.'s recommendations (10) . Specifically, Level I refers to evidence with at least one validation study from Category A, or one or more validation studies from Category B with consistent results. Level II evidence includes at least one study from Category B (or more than one if the results are inconsistent) or two or more studies from Category C. Level III evidence includes at least one study from Category C (or more than one with consistent or inconsistent results), and Levels IV and V evidence includes studies from Category D. Supplementary Table 2 shows the criteria for LOE determination on the basis of category and the number of studies.
A prognostic test is useful for determining the risk of an outcome independent of treatment, whereas a predictive test is useful for determining the best choice of treatment (10) . Studies were organized by the endpoints analyzed: distant recurrence, local recurrence, overall survival (OS), and response to neoadjuvant or adjuvant chemotherapy. If the endpoint was described as "metastasis-free survival," we treated it as a study of distant recurrence. We documented studies in which breast cancer-specific survival is reported separately from or instead of OS. In addition, we documented the estrogen receptor status and lymph node status proportions in the enrolled ESBC population.
Comparison of the magnitude of clinical benefit to the risk of toxic effects associated with therapy is not specifically required in the framework proposed by Simon et al. to deem a test as clinically useful (10) . Moreover, no published criteria exist on what constitutes a minimum ratio of benefit to toxic effects for assays in ESBC, and the cutoff may depend on the clinical situation. For example, a prognostic test may be clinically useful to some patients (eg, patients with multiple comorbidities) if the risk of recurrence is so low that it outweighs the risk of chemotherapy-associated toxic effects. We, therefore, elected to report the mean difference in outcomes for women in the studies between category levels of the test. For tests with only two categories of risk, we report the differences in the estimated risks between the categories. For a test with more than one category, we report the difference in risk between the highest and the lowest categories.
Critical Appraisal
Two investigators independently graded the studies by the elements specified in the framework developed by Simon et al. (10) . If the investigators' grade assignments were dissimilar, a third investigator reviewed the article and finalized the grading.
The current version of Adjuvant! Online for breast cancer, Version 8, does not include molecular biomarkers. We decided to include Adjuvant! Online in the evidence review because it is used by physicians and patients in discussing the potential toxicities, costs, and benefits of adjuvant chemotherapy (7, 8) and has been considered a comparator to the risk stratifiers summarized by Ross et al. (9) . We modified the framework of Simon et al. to expand the scope of evaluation to include stratifiers regardless of inclusion of tumor biomarker data. In the framework, we substituted the term "archived tissue" for the more inclusive term "previously collected clinicopathological data." Hence, a study of Adjuvant! Online could be assigned to Category B if the data had been collected prospectively using a prespecified protocol. The value of such a design is the rigor with which data are collected and the ability to limit recall bias.
We also examined studies that reported on changes in clinical practices and economic implications of risk stratifiers (16) . Among these, decision-impact studies evaluate the influence of stratifiers on real-world clinical decisions and practice patterns. Outcome studies evaluate the implications of the risk stratifiers from a broader perspective of patient-centered concerns, such as life expectancy and quality of life, which might be difficult to assess in clinical studies because of limited duration of follow-up or limitations in the statistical power of the study to detect a statistically significant effect. Economic studies further broaden the perspective to include the costs associated with the adoption of technologies to third-party payers and/or to society in general. We documented the studies that have been conducted for each of the stratifiers, but criteria for assigning such studies to categories for LOE determinations have not been published.
Statistical Analysis
We summarized the number and proportion of studies in each LOE determination category. We also report proportional change in clinical decisions and/or recommendations associated with use of the stratifier; two-sided P values from the χ 2 test and/or 95% confidence intervals are reported if provided. We report costeffectiveness estimates for studies of economic implications among stratifiers including information on the perspective of the analysis, country, and comparators. If use of the stratifier saved costs and improved outcomes, the amount of savings is reported. If use of the stratifier increased costs and improved outcomes, we report the incremental cost-effectiveness ratio. The probability computed in a sensitivity analysis of being below a threshold level of cost-effectiveness was reported if provided.
Search Results
The electronic search identified 4558 articles (Figure 1 ). Almost 92% of the articles (n = 4183) were excluded during the initial abstract screening. The remaining 375 articles were retrieved for full review by investigators. Three hundred and nineteen articles were excluded because they did not specifically pertain to the included stratifiers (n = 154), were reviews or contained no primary or new data (n = 114), were focused on methodological aspects of analyzing data (n = 16), or were duplicate studies or not relevant to prognosis, prediction, clinical practice changes, or economics (n = 35). Among the remaining 56 articles, 31 studied the 21-gene recurrence score, 14 studied the 70-gene signature, 1 studied the 5-gene expression index, 3 studied the 5-antibody IHC panel, 1 studied the 14-gene signature, and 12 studied Adjuvant! Online. Crude agreement between raters on grade assessment was 82%, and chancecorrected agreement was 0.72 as measured by the kappa coefficient. The most common reason for lack of full agreement was difficulty determining if the study satisfied criteria for assessing the test's ability to predict response to chemotherapy. Specifically, three studies reported different risks of recurrence on the basis of chemotherapy regimen with Adjuvant! Online (17-19) but did not provide statistically significant differences in risks. In these instances, the studies were found to show clinical validity/utility of predicting recurrence risk but not of response to chemotherapy.
Clinical Risk Prediction and Response to Therapy
No Category A study has yet been completed for any of these ESBC risk stratifiers; randomized controlled trials are ongoing 
is evaluating the effect of chemotherapy combined with hormonal therapy against hormonal therapy alone for patients with intermediate risk as determined by the 21-gene recurrence score (20) . The Rx for POsitive NoDe, Endocrine Responsive (RxPONDER) Breast Cancer trial is studying the efficacy of endocrine therapy with and without chemotherapy in women with hormone receptorpositive, HER2-negative breast cancer, 1-3 positive nodes, and a 21-gene recurrence score result of 25 or less (21) . The Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial is examining the prognostic capabilities of the 70-gene assay as compared with current clinicopathological factors (22) .
Eight studies satisfied Category B criteria (Table 3) , seven of which provide evidence of the 21-gene recurrence score's abilities to predict distant recurrence, local recurrence, or survival. This evidence is on the basis of archived tissues from randomized trials conducted by the National Surgical Adjuvant Breast and Bowel Cancer Project [NSABP B-14 (11, (23) (24) (25) , NSABP B-20 (12, (23) (24) (25) ] and Southwest Oncology Group (SWOG-8814) (26), Eastern Cooperative Oncology Group (ECOG-E2197) (27) as well as the translational research cohort of the Arimidex, Tamoxifen, Alone or in Combination (TransATAC) Trial (28) . Three of these seven studies showed the ability of the 21-gene recurrence score to independently predict response to adjuvant chemotherapy (12, 23, 26) . Using archived tissue from the NSABP studies (B-14 and B-20), Ross et al. (25) reported on the ability of the 5-antibody IHC panel to predict distant recurrence and OS. Though Jerevall et al. prospectively assessed two element genes of the 5-gene expression index, HOXB13 and IL17BR, in two studies, both failed to satisfy the inclusion criteria for our analysis (29, 30) . No Category B studies were reported on the 5-gene expression index. Using data from NSABP B-14 and B-20, Tang et al. showed that Adjuvant! Online independently predicted distant recurrence and predicted benefit to chemotherapy on the basis of OS but not on distant recurrencefree interval, disease-free survival, or breast cancer-specific mortality (23). Paridaens et al. reported on Adjuvant! Online's recurrence risk estimates in the International Breast Cancer Study Group Trial 11-93 but did not report the statistical significance of the predictions and thus did not satisfy criteria for inclusion in the metaanalysis as a validation study (31) .
Twenty-two studies satisfied Category C criteria (Table 3) (7, 14, (17) (18) (19) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . Four studies were observational studies of existing hospital registries and concerned Adjuvant! Online (7, (17) (18) (19) , and nine studies used prospective, observational methods to assess the prognostic and predictive value of the 70-gene signature (33, 34, 38, (40) (41) (42) 44, 47, 48) . Another nine studies satisfied Category C criteria for the remaining three stratifiers: five for the 21-gene recurrence score (35) (36) (37) 39, 45) , two for the 5-antibody IHC panel (32, 43) , and one each for the 5-gene expression index (14) and 14-gene signature (46) . There were only four Category D studies for clinical validity/utility-two each for the 21-gene recurrence score (49, 50) and the 70-gene signature (51, 52) .
With multiple studies satisfying Category B criteria, only the 21-gene recurrence score satisfied the determination of Level I evidence for prognosis of distant recurrence, OS, and response to adjuvant chemotherapy (Table 4) . With one Category B study, the 21-gene recurrence score also satisfied Level II evidence for predicting local recurrence. Simon et al. recommend that, "For a Category B study to be sufficient to change practice . . . the results must be confirmed using specimens from a second Category B study based on archived tissue from a different trial that has been designed, conducted, and analyzed in a similar, if not identical, manner" (10) . Based on their recommendation, the 5-antibody IHC panel satisfied the determination of Level II evidence for estimating risk of distant recurrence and OS with one Category B and two Category C studies for each outcome. With one Category B study and several Category C studies, Adjuvant! Online satisfied Level II evidence determination for prediction of distant recurrence, OS, and chemotherapy response. The 70-gene signature, despite having no Category B studies, satisfied Level II evidence for estimating risk of distant recurrence and OS with two or more Category C studies for each endpoint. With only one Category C study each, the 5-gene expression index satisfied Level III evidence for distant recurrence only and 14-gene signature satisfied Level III evidence for distant recurrence and OS.
Several studies have directly compared stratifiers. Using data from randomized trials NSABP-B14 and NSABP-B20, Tang et al. found that both the 21-gene recurrence score and Adjuvant! Online independently predicted distant recurrence (23) . Adjuvant! Online predicted chemotherapy benefit only when based on OS, whereas the 21-gene recurrence score was predictive of chemotherapy benefit based on breast cancer-specific mortality and distant recurrence-free interval measures in addition to OS. The 21-gene recurrence score was validated to predict response to adjuvant chemotherapy. This study satisfies Category B criteria for a study comparing two stratifiers. Buyse et al. found that the 70-gene signature had similar sensitivity (90% vs 87%) but higher specificity (42% vs 29%) in predicting metastasis within 5 years compared with Adjuvant! Online (34) . Sensitivity also was similar between these stratifiers in predicting death within 10 years (84% vs 82%); specificity was higher for the 70-gene signature (42% vs 29%) (34) . The abilities of the 70-gene signature and Adjuvant! Online to predict disease-free survival were similar.
Changes in Practice Patterns
Fifteen studies on the effects of stratifiers in clinical recommendations and actual decisions were published (Table 5 ) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) . Nine studies had a retrospective design and the other six studies had a prospective design. Studies varied in whether: 1) the decision maker was a clinician, an expert panel, or a patient; 2) the endpoint was a change in recommendation or actual decision; and 3) the control arm was recommendation without use of the stratifier, a standard guideline (eg, St Gallen, National Cooperative Cancer Network, Dutch Institute for Healthcare Improvement), or another stratifier.
Ten studies examined the influence of the 21-gene recurrence score on treatment recommendations and/or decisions (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) . One study was conducted as a prospective analysis of the treatment impact of the 21-gene recurrence score (59) . Overall, the 21-gene recurrence score was associated with a change in 20.6%-74.0% of treatment recommendations and/or decisions, depending on the control used for comparison. One prospective study of the 70-gene signature reported a 14.5% increase in recommendations of adjuvant treatment when compared with the Dutch Institute for Healthcare Improvement guidelines (63) . Four prospective studies of clinical practice changes were identified for Adjuvant! Online (64) (65) (66) (67) . Three studies involved multidisciplinary clinical teams, with 0.9%-12.7% change in treatment recommendations. A group randomized controlled trial of 405 patients (58 physicians) reported a 9.4% reduction in any treatment (P = .06) and 1.4% increase in use of chemotherapy (P = .80). To our knowledge, no studies have been published on the influence of the other stratifiers on clinical practice changes.
Health Economic Implications
Eleven studies have been published on health economic implications of the stratifiers (Table 6 ) (56, 58, (68) (69) (70) (71) (72) (73) (74) (75) (76) . Studies varied in perspective, whether societal and/or health care payer; country; duration of analysis horizon; and comparator to the stratifier. Studies assessed the economics of the 21-gene recurrence score against recommendations and/or decisions made without the recurrence score (56, 58, 71) , guideline-recommended treatment (68) (69) (70) 72) , and against Adjuvant! Online (73). The 21-gene recurrence score was reported as cost-saving compared with guideline-directed recommendations in the United States analyzed from a societal perspective (68, 72) or a health care payer perspective (56) . The stratifier was cost-increasing in studies of its economic implications in Japan, Canada and Israel, with the estimates of cost-effectiveness varying between $3848 and $63 054 (58, (69) (70) (71) 73) . Three studies reported on the health economic implications of the 70-gene signature compared with guidelines or another stratifier (Table 6) (74) (75) (76) . Compared with St Gallen guideline-based treatment, the cost-effectiveness of the 70-gene signature was $55 556 per quality-adjusted life year gained in Japan from a societal perspective (75) , whereas it was cost-saving in an analysis from a European health care payer perspective (76) . From a US health care payer perspective and compared with recommendations based on Adjuvant! Online, the cost-effectiveness of the 70-gene signature was approximately $10 000 per quality adjusted life year gained (74) . To our knowledge, no studies have been published on the health economic implications of the other stratifiers.
Discussion
Substantial effort during the past decade has gone into the research and development of novel stratifiers to predict the risk of recurrence, survival, and the response to adjuvant chemotherapy of women with ESBC. Results of more than 50 studies have been published on the clinical validation, changes in clinical practice, and economic implications of these stratifiers. Moreover, criteria have been evolving for grading the quality of the studies and determining LOE. The most notable change has been the creation of a new category (Category B) for prospective studies using archived tissues, agreed to be of a quality between traditional, prospective clinical trials (Category A) and prospective, observational studies (Category C) (10) . To accommodate comparisons with stratifiers that might not include molecular markers, we suggested a modification: Category B criteria shall be satisfied if the stratifying data were collected and analyzed in a manner consistent with the rigorous standards of a prospective clinical trial. Such trials are common among those conducted by established oncology study groups.
The development of clinical guidelines by the American Society of Clinical Oncology and the National Comprehensive Cancer Network relies on systematic reviews of the literature and on evidence grading. In 2007, using the older LOE determination and the studies published to that point, the American Society of Clinical Oncology determined that the 21-gene recurrence score satisfied Level II evidence for predicting recurrence risk, and Level III evidence for predicting response to adjuvant chemotherapy (4). The American Society of Clinical Oncology also concluded that the 70-gene signature satisfied Level III evidence. The National Comprehensive Cancer Network counseled (on the basis of a thorough review of similar evidence at the time) that both Adjuvant! Online and the 21-gene recurrence score satisfied criteria for being considered part of the process for determining risk (77) .
Applying the revised evidence-grading criteria to literature published before 2011, we found that the 21-gene recurrence score satisfies the criteria for Level I evidence determination for predicting distant recurrence risk, OS, and response to adjuvant chemotherapy, as well as Level II evidence for predicting risk of local recurrence. The 70-gene signature, 5-antibody IHC panel, and Adjuvant! Online satisfy Level II evidence for predicting risk of distant recurrence and OS. Adjuvant! Online also satisfied Level II evidence for predicting chemotherapy response. Other stratifier-outcome combinations have yet to exceed Level III evidence determination. A Category B study compared the 21-gene recurrence score with Adjuvant! Online, finding the 21-gene recurrence score to be more predictive of both distant recurrence and response to adjuvant chemotherapy (23) . With only one study, this satisfies Level II evidence for superiority of the 21-gene gene recurrence score over Adjuvant! Online. On the basis of one Category C study, the 70-gene signature was found to have Level III evidence for the ability to predict recurrence risk superior to that of Adjuvant! Online (34). Adjuvant! Online or a control pamphlet 9.4% reduction in any treatment (P = .06); 1.4% increase in chemotherapy chosen (P = .80) (node-negative patients only)
Applying the evidence-grading framework and interpreting its implications carries potential limitations. Despite the thoughtfulness and clarity in defining the criteria of grading systems, there were instances in which a lack of consistency in reporting both the design and findings of studies created difficulties in assigning a study to a category. Recent publications appear to be more complete, perhaps indicating a greater awareness of the expectations of review groups. During grading of the studies, we also took into consideration sample size, homogeneity of study populations, and whether preventative steps were taken against sampling biases by taking consecutive patients or patients who are representative of the overall population. One limitation of the new grading framework is that it does not provide guidance in the evaluation of composite signatures such as that provided by the 5-gene expression index. With continuous evolution of breast cancer gene signatures and interests in comparing, contrasting, and combining signatures, there is potential for the development of more composite assays. It is, therefore, important for clinical and health technology assessment authorities to confirm these validation criteria for the new generation of molecular diagnostics.
We also sought, in the design phase of the project, to grade evidence on changes in clinical practice and economic implications of stratifiers. However, the absence of a clear framework for grading such studies combined with the inconsistency in reporting these findings precluded offering a credible grading of these studies. Instead, we elected to use the simple and straightforward approach of documenting whether or not such studies had been performed. This task highlighted a need for the development of a system similar to that used here to evaluate the quality of clinical validity/utility studies for use in the appraisal of evidence concerning the real-world effects on clinical practice patterns, long-term outcomes, and costs.
During the coming years, more studies will be conducted on these and other stratifiers under development. Moreover, as often happens in oncological therapeutics, we anticipate that the time is fast approaching when the next generation of stratifiers will need to be compared directly against existing and validated stratifiersrather than merely clinicopathological factors-for the evidence to be considered strong enough to compel a change in clinical practice.
